pERK Expression in Erlotinib-treated Patients with Advanced Pancreatic Cancer: a Translational Subgroup Analysis From the Randomized AIO-PK0104 Phase III Trial

被引：0
|
作者：
Boeck, S. [1 ,2 ]
Ormanns, S. [3 ]
Laubender, R. P. [4 ]
Jung, A. [3 ]
Siveke, J. T. [5 ]
Haas, M. [1 ,2 ]
Kirchner, T. [3 ]
Heinemann, V. [1 ,2 ]
机构：
[1] Univ Munich, Klinikum Grosshadern, Dept Internal Med 3, D-8000 Munich, Germany
[2] Ctr Comprehens Canc, Munich, Germany
[3] Univ Munich, Dept Pathol, Munich, Germany
[4] Univ Munich, Inst Med Informat Biometry & Epidemiol, Munich, Germany
[5] Tech Univ Munich, Klinikum Rechts Isar, Dept Internal Med 2, D-8000 Munich, Germany
来源：
EUROPEAN JOURNAL OF CANCER | 2012年 / 48卷
关键词：
D O I：
10.1016/S0959-8049(12)72275-X
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
477
引用
收藏
页码：148 / 148
页数：1
相关论文
共 50 条
  • [1] pERK, pAKT and p53 as tissue biomarkers in erlotinib-treated patients with advanced pancreatic cancer: a translational subgroup analysis from AIO-PK0104
    Steffen Ormanns
    Jens T Siveke
    Volker Heinemann
    Michael Haas
    Bence Sipos
    Anna Melissa Schlitter
    Irene Esposito
    Andreas Jung
    Rüdiger P Laubender
    Stephan Kruger
    Ursula Vehling-Kaiser
    Cornelia Winkelmann
    Ludwig Fischer von Weikersthal
    Michael R Clemens
    Thomas C Gauler
    Angela Märten
    Michael Geissler
    Tim F Greten
    Thomas Kirchner
    Stefan Boeck
    BMC Cancer, 14
  • [2] pERK, pAKT and p53 as tissue biomarkers in erlotinib-treated patients with advanced pancreatic cancer: a translational subgroup analysis from AIO-PK0104
    Ormanns, Steffen
    Siveke, Jens T.
    Heinemann, Volker
    Haas, Michael
    Sipos, Bence
    Schlitter, Anna Melissa
    Esposito, Irene
    Jung, Andreas
    Laubender, Ruediger P.
    Kruger, Stephan
    Vehling-Kaiser, Ursula
    Winkelmann, Cornelia
    von Weikerstahl, Ludwig Fischer
    Clemens, Michael R.
    Gauler, Thomas C.
    Maerten, Angela
    Geissler, Michael
    Greten, Tim F.
    Kirchner, Thomas
    Boeck, Stefan
    BMC CANCER, 2014, 14
  • [3] IDO1 expression as biomarker in erlotinib-treated patients with advanced pancreatic cancer: translational results from the AIO-PK0104 phase III trial
    Kruger, S.
    Ormanns, S.
    Roesgen, V.
    Legenstein, M. -L.
    Haas, M.
    Westphalen, C. B.
    Duewell, P.
    Schnurr, M.
    Heinemann, V.
    Kirchner, T.
    Boeck, S.
    ONCOLOGY RESEARCH AND TREATMENT, 2017, 40 : 235 - 235
  • [4] Phosphorylated ERK (pERK) as biomarker in patients with advanced pancreatic cancer treated with erlotinib within a randomized phase III trial (AIO-PK0104)
    Boeck, Stefan Hubert
    Ormanns, Steffen
    Laubender, Ruediger Paul
    Jung, Andreas
    Siveke, Jens T.
    Haas, Michael
    Neumann, Jens
    Vehling-Kaiser, Ursula
    Winkelmann, Cornelia
    von Weikersthal, Ludwig Fischer
    Clemens, Michael R.
    Gauler, Thomas C.
    Marten, Angela
    Klein, Stefan
    Kojouharoff, Georgi
    Geissler, Michael
    Greten, Tim F.
    Kirchner, Thomas
    Heinemann, Volker
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (04)
  • [5] EGFR pathway biomarkers in erlotinib-treated patients with advanced pancreatic cancer: translational results from the randomised, crossover phase 3 trial AIO-PK0104
    Boeck, S.
    Jung, A.
    Laubender, R. P.
    Neumann, J.
    Egg, R.
    Goritschan, C.
    Vehling-Kaiser, U.
    Winkelmann, C.
    von Weikersthal, L. Fischer
    Clemens, M. R.
    Gauler, T. C.
    Maerten, A.
    Klein, S.
    Kojouharoff, G.
    Barner, M.
    Geissler, M.
    Greten, T. F.
    Mansmann, U.
    Kirchner, T.
    Heinemann, V.
    BRITISH JOURNAL OF CANCER, 2013, 108 (02) : 469 - 476
  • [6] EGFR pathway biomarkers in erlotinib-treated patients with advanced pancreatic cancer: translational results from the randomised, crossover phase 3 trial AIO-PK0104
    S Boeck
    A Jung
    R P Laubender
    J Neumann
    R Egg
    C Goritschan
    U Vehling-Kaiser
    C Winkelmann
    L Fischer von Weikersthal
    M R Clemens
    T C Gauler
    A Märten
    S Klein
    G Kojouharoff
    M Barner
    M Geissler
    T F Greten
    U Mansmann
    T Kirchner
    V Heinemann
    British Journal of Cancer, 2013, 108 : 469 - 476
  • [7] EGFR pathway biomarkers in erlotinib-treated patients with advanced pancreatic cancer: translational results from a randomized, cross-over AIO phase III trial
    Boeck, S.
    Jung, A.
    Laubender, R. P.
    Neumann, J.
    Egg, R.
    Goritschan, C.
    Vehling-Kaiser, U.
    Winkelmann, C.
    von Weikersthal, Fischer L.
    Clemens, M. R.
    Gauler, T.
    Maerten, A.
    Klein, S.
    Kojouharoff, G.
    Barner, M.
    Geissler, M.
    Greten, T. F.
    Mansmann, U.
    Kirchner, T.
    Heinemann, V
    ONKOLOGIE, 2011, 34 : 216 - 216
  • [8] Impact of hand-foot skin reaction on treatment outcome in patients receiving capecitabine plus erlotinib for advanced pancreatic cancer: A subgroup analysis from AIO-PK0104
    Kruger, Stephan
    Boeck, Stefan
    Heinemann, Volker
    Laubender, Ruediger P.
    Vehling-Kaiser, Ursula
    Waldschmidt, Dirk
    Kettner, Erika
    Maerten, Angela
    Winkelmann, Cornelia
    Klein, Stefan
    Kojouharoff, Georgi
    Gauler, Thomas C.
    Von Weikersthal, Ludwig Fischer
    Clemens, Michael R.
    Geissler, Michael
    Greten, Tim F.
    Hegewisch-Becker, Susanna
    Modest, Dominik P.
    Stintzing, Sebastian
    Haas, Michael
    ACTA ONCOLOGICA, 2015, 54 (07) : 993 - 1000
  • [9] Molecular markers of the EGFR pathway in erlotinib-treated patients with advanced pancreatic cancer (APC): Translational analyses of a randomized, cross-over AIO phase III trial
    Boeck, S. H.
    Jung, A.
    Laubender, R. P.
    Neumann, J.
    Egg, R.
    Goritschan, C.
    Vehling-Kaiser, U.
    Winkelmann, C.
    von Weikersthal, L. Fischer
    Clemens, M. R.
    Gauler, T. C.
    Marten, A.
    Klein, S.
    Kojouharoff, G.
    Barner, M.
    Geissler, M.
    Greten, T. F.
    Mansmann, U.
    Kirchner, T.
    Heinemann, V.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [10] Correlation of hand-foot skin reaction (HFS) with treatment efficacy in pancreatic cancer (PC) patients (pts) treated with gemcitabine/capecitabine plus erlotinib: A subgroup analysis from the AIO-PK0104 randomized, cross-over phase III trial in advanced PC
    Haas, Michael
    Boeck, Stefan Hubert
    Laubender, Ruediger Paul
    Modest, Dominik Paul
    Vehling-Kaiser, Ursula
    Waldschmidt, Dirk
    Kettner, Erika
    Maerten, Angela
    Winkelmann, Cornelia
    Klein, Stefan
    Kojouharoff, Georgi
    Gauler, Thomas C.
    Von Weikersthal, Ludwig Fischer
    Clemens, Michael
    Geissler, Michael
    Greten, Tim F.
    Hegewisch-Becker, Susanna
    Rubanov, Oleg
    Mansmann, Ulrich Robert
    Heinemann, Volker
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
12345